The company is positioned as a pioneer in microalgae biotechnology with three core strategic programs: functional lipids (Omega-3), natural proteins, and photosynthesis-based carbon capture technology. Fermentalg targets growth in food, feed, and environmental sectors, with products marketed globally including ΩRIGINS™ functional lipids and Galdieria Blue™ antioxidants.
Cyborg Score Rationale
Fermentalg demonstrates promising technology and growing revenue (11.5M EUR last year), but faces significant profitability challenges with negative EBITDA (-8.12M EUR) and negative margin (-71.31%), indicating pre-commercialization stage economics typical of biotech innovators.
Top Insights
Revenue growth accelerating: Natural Solutions segment grew from 4.04M EUR to 11.42M EUR year-over-year, representing 182% growth
Listed on Euronext Growth Paris in 2024, signaling transition from private biotech to public markets
Strategic focus on replacing two depleted resources: wild fish (omega-3) and petroleum derivatives
Negative profitability metrics suggest company is in heavy R&D and commercialization phase with path to profitability unclear
Named Competitors
Fish-based Omega-3 Supplements — Traditional omega-3 suppliers facing sustainability pressure
Synthetic Food Colorants — Chemical colorants being displaced by natural alternatives
Algae-based Ingredients — Growing segment of microalgae-derived nutritional products
Recent Developments
(January 2025) Participation in GOED Omega-3 Exchange conference in Athens, focusing on supply chain and AI impact in omega-3 sector
(2024) Listing on Euronext Growth Paris
(2023) Launch of BLUE ORIGINS AOX antioxidant product at Supply Side West
Open the full interactive Fermentalg report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.